Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Ixazomib Improves PFS as Frontline Maintenance in Multiple Myeloma

November 7th 2019

Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.

Dr. Waxman on the Future of Treatment in Multiple Myeloma

November 7th 2019

Adam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.

Anti-BCMA Approaches Ascending in Multiple Myeloma

November 7th 2019

Anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, have the potential to revolutionize the multiple myeloma treatment paradigm. At the 37 Annual CFS®, Sham Mailankody, MBBS, discussed the emerging BCMA-directed therapies that have shown the greatest potential.

Dr. Mailankody on CASSIOPEIA Results in Newly Diagnosed Multiple Myeloma

November 6th 2019

Sham Mailankody, MBBS, discusses results of the CASSIOPEIA trial in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Dr. Giralt on Transplant Eligibility Criteria in Multiple Myeloma

November 2nd 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses transplant eligibility criteria in multiple myeloma.

Dr. Tabbara on Treatment for Transplant-Eligible and -Ineligible Patients With Multiple Myeloma

November 1st 2019

Imad Tabbara, MD, discusses available treatment options for transplant-eligible and -ineligible patients with multiple myeloma.

Dr. Cohen on the DREAMM-2 Trial in Multiple Myeloma

October 31st 2019

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.

Dr. Mateos on Posthoc Analysis of ARROW Study in Multiple Myeloma

October 31st 2019

María-Victoria Mateos, MD, PhD, discusses the rationale for the posthoc analysis of the phase III ARROW study in multiple myeloma.

Dr. Usmani on CAR T Cells, Bispecific Antibodies, and ADCs in Multiple Myeloma

October 31st 2019

Saad Z. Usmani, MD, FACP, discusses the mechanisms of action of BCMA-targeted CAR T-cell therapy, bispecific monoclonal antibodies, and antibody-drug conjugates in multiple myeloma.

FDA Grants RMAT Designation to CAR T-Cell Therapy CT053 for Myeloma

October 31st 2019

The FDA has granted a Regenerative Medicine Advanced Therapy designation to the investigational anti-BCMA CAR T-cell therapy CT053 for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Kumar on Implications of BELLINI Trial in Relapsed/Refractory Multiple Myeloma

October 31st 2019

Shaji K. Kumar, MD, discusses the takeaways from the phase III BELLINI trial which tested venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Borrello Sheds Light on the Multiple Myeloma Treatment Paradigm

October 31st 2019

Ivan M. Borrello, MD, discusses the current multiple myeloma treatment paradigm.

Dr. Harrison on Subcutaneous Daratumumab and Isatuximab in Myeloma

October 29th 2019

Simon J. Harrison, MBBS, PhD, discusses the impact subcutaneous formulations of daratumumab and isatuximab could have in multiple myeloma.

Dr. Stadtmauer Discusses Promising Targets in Multiple Myeloma

October 29th 2019

Edward A. Stadtmauer, MD, section chief, Hematologic Malignancies, and Roseman, Tart, Harrow, and Shaffer Families’ President’s Distinguished Professor, Penn Medicine, University of Pennsylvania, discusses promising targets in multiple myeloma.

Dr. Waxman on Selinexor in Multiple Myeloma Treatment

October 25th 2019

Adam J. Waxman, MD, MS, discusses the STORM trial and using selinexor to treat patients with multiple myeloma.

Dr. Cho on Investigational BiTE Therapies in Multiple Myeloma

October 25th 2019

Hearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.

Daratumumab Triplet Nears EU Approval for Frontline Transplant-Ineligible Myeloma

October 18th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of daratumumab for use in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

Dr. Larson on the Impact of MRD on Treatment Decisions in Multiple Myeloma

October 17th 2019

Sarah M. Larson, MD, assistant professor of medicine, and director, Multiple Myeloma Program, University of California, Los Angeles, discusses the impact of minimal residual disease (MRD) on treatment decisions in multiple myeloma.

Dr. Waxman on the Role of Transplant in Multiple Myeloma

October 14th 2019

Adam J. Waxman, MD, MS, discusses the role of transplant in patients with multiple myeloma.

Myeloma Regimens Require Coping Mechanisms for Toxicity

October 14th 2019

Adam J. Waxman, MD, MS, discusses new and upcoming multiple myeloma treatments and how to optimally manage toxicities from these regimens.